Dose and frequency of administration of interferon-β affect its efficacy in multiple sclerosis

Clinical Drug Investigation

Volumn 23, Issue 9, 2003, Pages 551-559

  Sharief, Mohammed K ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CELL SURFACE RECEPTOR; GLATIRAMER; INTERFERON BETA SERINE; LIVER ENZYME; PLACEBO;

ANALYTICAL PARAMETERS; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; IMMUNOMODULATION; INJECTION SITE; LEUKOCYTE COUNT; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 0141836262     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323090-00001     Document Type: Review

References (29)

1. Clanet M. Interferon-beta in the treatment of multiple sclerosis: do clinical data support the existence of a ceiling effect? Clin Drug Invest 2001; 21: 307-18
2. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002; 59: 1507-17
3. Wandinger K-P, Stürzebecher C-S. Bielekova B, et al. Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001; 50: 349-57
4. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58: S3-9
5. Stürzebecher S, Maibauer R, Heuner A, et al. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J Interferon Cytokine Res 1999; 19: 1257-64
6. Witt PL, Storer BE, Bryan GT, et al. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β. J Immunother 1993; 13: 191-200
7. Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron® and Avonex™. J Interferon Cytokine Res 1998; 18: 967-75
8. Rothuizen LE, Buclin T, Spertini F, et al. Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999; 99: 131-41
9. Rudick RA, Ransohoff RM, Peppler R, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996; 40: 618-27
10. PRISMS Study Group. Randomised, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-504
11. PRISMS Study Group and University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36
12. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
13. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85
14. Simon JH. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. J Magn Reson Imaging 1997; 7: 29-37
15. McFarland HF, Stone LA, Calabresi PA, et al. MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler 1996; 2: 198-205
16. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758-66
17. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85
18. Trapp BD, Ransohoff RM, Fischer E, et al. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5: 48-57
19. Li DKB, Paty DW, UBC MS/MRI Analysis Research Group, et al. Magnetic resonance imaging results of the PRISMS trial: a randomized double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999; 46: 197-206
20. Chofflon M. Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. Eur J Neurol 2000; 7: 369-80
21. OWIMS Study Group. Evidence of interferon β-1a dose response in relapsing-remitting MS. Neurology 1999; 53: 679-86
22. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
23. Johnson KP, Brooks BR, Cohen JA. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76
24. O'Connor P. Comparison of outcome measures in interferon beta studies in relapsing-remitting multiple sclerosis. Neurology 1999; 52 (Suppl. 2): A498
25. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60
26. Antonetti F, Finocchiaro O, Mascia M, et al. A comparison of the biological activity of two recombinant interferon β preparations used in the treatment of relapsing multiple sclerosis. J Interferon Cytokine Res 2002; 22: 1181-4
27. Panitch H, Goodin DS, Francis G, et al. Randomized comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496-506
28. FDA memorandum. Comparative study of Rebif® to Avonex® and orphan exclusivity [online]. Available from URL: http://www.fda.gov/cber/products/ifnbser030702.htm [Accessed 2002 Apr 16]
29. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis. Neurology 2002; 58: 169-78